DK1103564T3 - Cancerantigener baseret på tumorsuppressorgen WT1-produkt - Google Patents

Cancerantigener baseret på tumorsuppressorgen WT1-produkt

Info

Publication number
DK1103564T3
DK1103564T3 DK99933205T DK99933205T DK1103564T3 DK 1103564 T3 DK1103564 T3 DK 1103564T3 DK 99933205 T DK99933205 T DK 99933205T DK 99933205 T DK99933205 T DK 99933205T DK 1103564 T3 DK1103564 T3 DK 1103564T3
Authority
DK
Denmark
Prior art keywords
product
tumor suppressor
suppressor gene
cancer antigens
antigens based
Prior art date
Application number
DK99933205T
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1103564(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of DK1103564T3 publication Critical patent/DK1103564T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99933205T 1998-07-31 1999-07-30 Cancerantigener baseret på tumorsuppressorgen WT1-produkt DK1103564T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (1)

Publication Number Publication Date
DK1103564T3 true DK1103564T3 (da) 2009-05-11

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99933205T DK1103564T3 (da) 1998-07-31 1999-07-30 Cancerantigener baseret på tumorsuppressorgen WT1-produkt

Country Status (15)

Country Link
US (7) US7030212B1 (da)
EP (3) EP1103564B1 (da)
JP (2) JP4422903B2 (da)
KR (1) KR100767554B1 (da)
CN (4) CN1560078B (da)
AT (1) ATE420112T1 (da)
AU (1) AU4932199A (da)
BR (1) BRPI9912663B8 (da)
CA (1) CA2337743C (da)
DE (1) DE69940264D1 (da)
DK (1) DK1103564T3 (da)
ES (1) ES2318898T3 (da)
HK (1) HK1038929B (da)
PT (1) PT1103564E (da)
WO (1) WO2000006602A1 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
DE60238958D1 (de) * 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
KR101399678B1 (ko) 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2530184C (en) 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
JP5239041B2 (ja) 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP5478260B2 (ja) * 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
US20140341939A1 (en) 2011-12-14 2014-11-20 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
EA201591168A1 (ru) 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
IN2014CH00391A (da) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
US20140220056A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
EP2982681B8 (en) 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen peptide conjugate vaccine
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
ES2916834T3 (es) 2014-09-27 2022-07-06 Sumitomo Pharma Co Ltd Composición farmacéutica para inyección
CA2997757A1 (en) * 2015-09-10 2017-03-16 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
IL260988B2 (en) * 2016-03-03 2023-03-01 Roussy Inst Gustave ptps-based vaccines against cancer
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
CA3090700A1 (en) 2018-02-12 2019-08-15 Fred Hutchinson Cancer Research Center Cyclin a1 specific t cell receptors and uses thereof
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
WO2020071551A1 (ja) * 2018-10-05 2020-04-09 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
AU2020334064A1 (en) 2019-08-20 2022-03-03 Fred Hutchinson Cancer Center T-cell immunotherapy specific for WT-1
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2022014249A (es) 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO1991007509A1 (en) 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
ES2268705T3 (es) 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
JP3904260B2 (ja) * 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
PT1435205E (pt) 1995-09-19 2010-02-04 Bayer Bioscience Gmbh Plantas que sintetizam um amido modificado, processo para a sua produção e amido modificado
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
JP2002534438A (ja) 1999-01-12 2002-10-15 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規治療法
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
EP1074267B1 (en) 1999-07-22 2006-03-15 Dainippon Sumitomo Pharma Co., Ltd. Induction of antigen-specific T cells by interferon
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
EP1548028B1 (en) * 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja) 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド

Also Published As

Publication number Publication date
EP1103564B1 (en) 2009-01-07
CN1178956C (zh) 2004-12-08
CA2337743C (en) 2015-07-07
EP1103564A1 (en) 2001-05-30
US7390871B2 (en) 2008-06-24
US9403886B2 (en) 2016-08-02
JP2010059172A (ja) 2010-03-18
ATE420112T1 (de) 2009-01-15
PT1103564E (pt) 2009-03-13
US7807792B2 (en) 2010-10-05
CN100560130C (zh) 2009-11-18
WO2000006602A1 (fr) 2000-02-10
HK1038929B (zh) 2005-05-06
EP2280031B1 (en) 2015-04-15
CN1560078A (zh) 2005-01-05
BRPI9912663A (pt) 2001-05-02
BRPI9912663B1 (pt) 2011-05-31
CN1762490A (zh) 2006-04-26
AU4932199A (en) 2000-02-21
US20060093615A1 (en) 2006-05-04
US7608685B1 (en) 2009-10-27
KR100767554B1 (ko) 2007-10-17
US7517950B2 (en) 2009-04-14
HK1153761A1 (en) 2012-04-05
EP2280031A1 (en) 2011-02-02
CA2337743A1 (en) 2000-02-10
HK1036073A1 (en) 2001-12-21
EP2048160B1 (en) 2015-01-07
KR20010072112A (ko) 2001-07-31
EP2048160A1 (en) 2009-04-15
US7030212B1 (en) 2006-04-18
CN102198266A (zh) 2011-09-28
HK1130069A1 (en) 2009-12-18
CN1560078B (zh) 2011-06-22
US20090281043A1 (en) 2009-11-12
US20160243209A1 (en) 2016-08-25
DE69940264D1 (de) 2009-02-26
CN1314916A (zh) 2001-09-26
EP1103564A4 (en) 2005-02-02
JP4422903B2 (ja) 2010-03-03
BRPI9912663B8 (pt) 2021-07-06
US20090143291A1 (en) 2009-06-04
JP5230579B2 (ja) 2013-07-10
US20050266014A1 (en) 2005-12-01
HK1038929A1 (en) 2002-04-04
ES2318898T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
AU4932199A (en) Cancer antigens based on tumor suppressor gene wt1 product
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
CY2016021I2 (el) Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
WO2001078768A3 (en) Targeted vaccine delivery systems
MXPA05002014A (es) Acidos nucleicos inmunoestimuladores.
GT200000103A (es) Trifluorbutenos nematocidas.
DE69213112D1 (de) Verbesserte Methoden zur Nukleinsäure-Amplifizierung
AU7357098A (en) Rapid production of autologous tumor vaccines by using hsv amplicon vectors
EP1731605A4 (en) CANCERANT PEPTIDES FROM WT1
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
PL372769A1 (en) Cyanoguanidine prodrugs
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
ATE279944T1 (de) Kombinationsimpfstoff zur steigerung der immunität gegen brucellose
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
DE69802329D1 (de) Verfahren zur Herstellung von 3,4 disubstituirten Dinitroanilinen
IT1286307B1 (it) Virus mixomatoso ricombinante, suo impiego per la produzione di un vaccino e relativo vaccino.
LV12722A (lv) Prv-1 gene and the use thereof
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
IT1256078B (it) Ligandi kit solubili
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.